CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

CINRYZE

RegulatoryapprovedCINRYZEPositive
AI Analysis

Summary

CINRYZE has received approval for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema, expanding its therapeutic indication.

Outcome Details

Product approval information indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE

Importance:6/10
Sentiment:
0.70
FDA approvalHAEhereditary angioedemaprophylaxisC1 esterase inhibitor

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on August 31, 2026 7:02 PM

Read Original